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EDITORIAL
South African Guidelines Excellence (SAGE): Clinical 
practice guidelines – quality and credibility
Over the past 15 years, the processes for developing 
clinical practice guidelines (CPGs) have shifted from 
their being written by experts (or based on expert 
opinion) to being largely written by methodologists. 
CPGs are quality improvement tools, and although 
they are presented in different ways, their aims are commonly to 
standardise care, improve its quality and safety, reduce wastage, 
decrease unnecessary costs, and improve access to care and patient 
outcomes.[1-3]
With the emergence of international collaborations such as 
the Guidelines International Network (G-I-N),[4] there have been 
concerted attempts to standardise CPG writing practices across 
countries, to increase the credibility of the final products.[5-7] 
Without adherence to rigorous guideline development and reporting 
standards, the considerable time and effort put into developing 
guidelines may be wasted, as intended users may not have confidence 
in the recommendations made.
South Africa (SA) is an emerging African leader in CPGs. 
However, there is room for improvement if SA CPG activities are to 
match global standards.[7] In April 2014, the SAMJ signalled on its 
website the appointment of an editorial subcommittee whose specific 
mandate would be to review guidelines submitted for publication. 
The SAMJ has regularly published guidelines and recommendations 
for the management of a variety of conditions. These will in future 
be adjudicated using the AGREE II instrument (www.agreetrust.org). 
An editorial in the May issue entitled ‘AGREE to disagree’ recognised 
the important role that CPGs play in setting standards of clinical 
practice in SA, and introduced a formalised mechanism to assess 
CPG quality prior to publication.[8]
This editorial outlines and discusses key aspects of CPG quality, 
and sets the scene for the South African Guidelines Excellence (SAGE) 
project, funded for 3 years by the South African Medical Research 
Council. This innovative research partnership aims to improve the 
quality and reach of SA primary care CPGs. Using stakeholder-
driven processes, SAGE will provide tools to assist effective SA CPG 
activities in developing, adapting, adopting, contextualising and 
implementing primary care CPGs.
International standards for 
guideline developers
Between 2011 and 2013, three standards were independently 
proposed, to assist CPG developers in addressing key issues of quality 
(Institute of Medicine (IOM) 8 standards,[2] G-I-N 11 standards,[4] 
and McMaster University group 18 standards[9]). Concurrently, two 
checklists were independently developed to appraise CPG quality. The 
AGREE II checklist (Appraisal of Guideline ResEarch and Evaluation) 
uses six domains incorporating 23 items (each scored 1 - 7),[10] while 
the iCAHE checklist (International Centre for Allied Health Evidence) 
provides a simpler alternative for policy makers and clinicians, with 
seven domains incorporating 14 binary items. [11] Table 1 compares the 
items in each checklist, using the AGREE II domains to standardise 
comparison. Domains common to all instruments are ‘stakeholder 
involvement’, ‘underlying evidence’, ‘currency’ and ‘clarity’.
Stakeholder involvement. Stakeholder (end-user) involvement 
directly links CPGs to ownership, and downstream implementation. It 
is therefore an essential initial step to identify all relevant stakeholders 
within a CPG’s scope and purpose, and then determine the role each 
stakeholder might play in the CPG development process. This assists 
determination of clear terms of reference. Stakeholder engagement 
can either occur individually (‘experts’ working with the methodology 
team) or as a collective (providing feedback on CPG drafts, or at 
public consultations).
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Scope and purpose. The CPG purpose intrinsically links with end-
users and the target audience (people to whom the guidance is being 
directed). The CPG scope also underpins the framing of the research 
questions. For instance, for a CPG aimed at primary care clinicians, 
research questions would not be raised about care provided in other 
sectors. Defining scope and purpose early, and clearly, assists in 
determining which stakeholders need to be engaged, how, and in 
what ways.
Independence. It is critical that everyone involved in CPG 
development is identified, their qualifications listed and their role 
on the guideline team described, and potential conflicts of interest 
declared in writing throughout the CPG activity. Funding for the 
CPG and endorsements should be stated clearly.[12] Independence 
is essential when sourcing and critiquing the evidence, so that one 
person’s or group’s view of the literature does not dominate.[13]
Underlying evidence. A good-quality CPG should include a 
comprehensive ‘Methods’ section, which outlines the research 
questions, how the literature was accessed (databases, search terms/
key words, inclusion/exclusion criteria), how the research was 
critiqued (hierarchy of evidence, critical appraisal tools), how data 
were extracted, and how the strength of the body of evidence was 
determined and reported for each recommendation. A comprehensive 
reference list of included papers should be provided, so that end-users 
can identify literature underpinning each recommendation.
Currency. With an estimated 1.8 million peer-reviewed articles 
published in academic journals by the end of 2012,[14] ensuring that 
CPGs are based on current evidence is a constant challenge. This 
requires regular updating, using the protocols established during 
initial CPG development. Before updating, CPG developers should 
first identify new issues that have arisen since the previous CPG was 
published. They should also consider the relevance of the questions 
‘carried forward’ from the last CPG. Literature searches should be 
undertaken from the date of completion of the previous search to 
the present, to update the evidence base. The relevance of any new 
findings should be factored into previous recommendations, using a 
standard approach.[1]
Clarity. Clearly written CPGs and comprehensive supporting 
documentation are essential to ensure that end-users can be confident 
that they can trust the recommendations. This reduces barriers to 
uptake and implementation.[2] Moreover, the use of standard clear 
wording when writing recommendations is encouraged, to clearly 
link the strength of the evidence body with the wording of the 
recommendation.[6,15]
Conclusion
In this editorial, the first in a series of six, we present issues critical 
to CPG development and uptake, relevant to SA and beyond. 
While recent local efforts to improve CPG quality and credibility 
in SA are commendable,[8,7] opportunities to progress SA CPG 
quality and uptake are limited by the lack of a central, nationally 
recognised and accepted CPG development unit. Such a unit has 
the potential to significantly increase SA efforts to improve and 
standardise high-quality, credible CPG development, reporting and 
uptake. To this end, the Project SAGE team is engaging in a 
3-year stakeholder-driven process that aims to better understand the 
guideline development arena in SA, and improve the standard of local 
guideline development, adaptation, contextualisation, and ultimately 
implementation of primary healthcare guidelines.
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